---
schema_version: "secwatch.filing_event.v1"
accession: "0001723128-23-000017"
form_type: "8-K"
ticker: "AMRX"
cik: "0001723128"
company_name: "Amneal Pharmaceuticals, Inc."
filed_at: "2023-05-05T23:59:59+00:00"
generated_at: "2026-06-15T17:11:25.493430+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Amneal Q1 revenue $558M (+12% YoY); adj. EBITDA $116M (+16%); reaffirms FY guidance

## Summary
- Net revenue $558M, up 12% YoY; driven by generics, specialty (Rytary, Unithroid), and AvKARE expansion.
- Net loss $7M ($0.05 loss per share) vs $2M loss last year; adjusted EPS $0.12 flat YoY.
- Adjusted EBITDA $116M, up 16% YoY; company reaffirms full-year 2023 guidance.
- Fourth and largest injectables facility successfully inspected; IPX203 PDUFA date June 30.

## SEC filing metadata
- accession: 0001723128-23-000017
- form_type: 8-K
- ticker: AMRX
- cik: 0001723128
- company_name: Amneal Pharmaceuticals, Inc.
- filed_at: 2023-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1723128/000172312823000017/0001723128-23-000017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1723128/000172312823000017/amrx-20230505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001723128-23-000017
- JSON: https://secwatch.observer/filing/0001723128-23-000017.json
- Plain text: https://secwatch.observer/filing/0001723128-23-000017.txt

## Key facts
- Earnings Releases
  Amneal Pharmaceuticals, Inc. reported first quarter ended March 31, 2023 results: revenue $558 million, net income $7 million, EPS $0.05. Guidance reaffirmed.
  - Period: first quarter ended March 31, 2023
  - Revenue: $558 million
  - Net income: $7 million
  - EPS: $0.05
  - Guidance: reaffirmed
  - Result: reported results
  source text: Q1 2023 Net Revenue of $558 million; GAAP Net Loss of $7 million; Diluted Loss per Share of $0.05 ‒ ‒ Adjusted EBITDA (1) of $116 million; Adjusted Diluted EPS (1) of $0.12 ‒ ‒ Affirming 2023 Full Year Guidance
  evidence_url: https://www.sec.gov/Archives/edgar/data/1723128/000172312823000017/0001723128-23-000017-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.